ANIK Anika Therapeutics Inc.

Anika Launches the WristMotion® Total Wrist Arthroplasty System at the American Society for Surgery of the Hand Annual Meeting

Anika Launches the WristMotion® Total Wrist Arthroplasty System at the American Society for Surgery of the Hand Annual Meeting

Designed to preserve natural motion and maximize stability, the WristMotion® Total Wrist Arthroplasty System provides an advanced solution for wrist arthritis and an alternative to wrist fusion

BEDFORD, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company, today announced its WristMotion® Total Wrist Arthroplasty (TWA) System was launched at the American Society for Surgery of the Hand (ASSH) 2021 annual meeting in San Francisco, CA. Previously available to select surgeons and patients during a limited launch beginning on June 30, 2021, the WristMotion TWA System is focused on alleviating pain and restoring function of an arthritic wrist joint. The WristMotion TWA System’s novel design maximizes carpal stability and enables rotational freedom, including the “dart thrower’s” motion.

“We are excited to offer surgeons and patients multiple options to treat wrist arthritis with our WristMotion family of products,” said Cheryl R. Blanchard, Ph.D., Anika’s President and CEO. “At Anika, we are committed to meaningful innovation and advancing solutions in areas with unmet needs that allow patients to remain active and engaged in the activities they love. Preserving motion and native anatomy are core pillars of our innovation philosophy, and the WristMotion TWA System is a key strategic addition to our portfolio.”

Designed in collaboration with Dr. Arnold-Peter C. Weiss and Dr. Randall Culp, the design of the WristMotion TWA System leverages over 12 years of data focused on stability and improving wrist implants for patients by incorporating Anika’s proprietary taper post fixation for long-term stability and anatomic design for the preservation of motion.

The WristMotion TWA System is a modular joint preservation system that replaces both the radial and carpal sides of the wrist joint for patients suffering from rheumatoid arthritis, osteoarthritis, or post-traumatic arthritis. The system incorporates Anika’s proven fixation technology in the central carpal taper post design, also used in the WristMotion Hemiarthroplasty System, which has been in clinical use since 2015, with over 2,600 cases performed to date1. The WristMotion TWA System also utilizes Anika’s dual curvature design feature in the carpal implant combined with the dorsal flange (or hood) which allows for greater range of extension due to the increased implant surface area2. Preclinical robotic testing has demonstrated that the combination of these features provides improved range of motion and rotational freedom compared to competitive devices, consistent with Anika’s design philosophy of preserving the complex kinematics of the native joints2.

“Historically, patients suffering with advanced wrist pain caused by arthritis or trauma were treated with older versions of total wrist arthroplasty systems or with wrist fusions. Existing total wrist arthroplasty implants on the market today may enable some wrist motion but are at higher risk of carpal loosening. Alternatively, a wrist fusion may severely limit a patient’s ability to move and use their wrist. Neither option restores wrist function, and that’s the core reason the WristMotion TWA System is a significant step forward for surgeons and patients,” said Arnold-Peter C. Weiss, M.D., Chief - Hand, Upper Extremity & Microvascular Surgery, Vice Chairman and Professor of Orthopaedics, Warren Alpert Medical School, Brown University.

The WristMotion TWA System has been available to select customers during a limited market release starting after the first case was performed by Dr. Weiss on June 30th. To-date, the early clinical feedback on instrumentation, surgical technique, and post-operative range of motion has been very positive.

“The WristMotion TWA System’s proprietary central threaded taper post helps ensure secure carpal fixation. This secure carpal fixation, coupled with the ability to adjust the height and tension of the wrist joint on the radial side rather than carpal, strengthens the implant’s stability and also preserves the natural center of rotation,” said William B. Geissler, MD, Alan E. Freeland Chair of Hand Surgery, Professor and Chief Division of Hand and Upper Extremity, University of Mississippi. Dr. Geissler was the first surgeon in Mississippi to implant the WristMotion TWA System. “It is truly the next generation of total wrist arthroplasty,” said Dr. Geissler.

The WristMotion TWA System, along with the WristMotion Hemiarthroplasty System, provide surgeons with multiple treatment options for different stages and severities of wrist arthritis. Both options are available in the United States, and the WristMotion Hemiarthroplasty System was recently launched in Europe.

To learn more about WristMotion, or to learn more about ordering it for a surgery, please visit .

1. As of July 31, 2021. Data on file.

2. Preclinical data on file. Results may not correlate to clinical performance.

About Anika

(NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. We partner with physicians to understand what they need most to treat their patients and we develop minimally invasive products that restore active living for people around the world. We are committed to leading in high opportunity spaces within orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair and bone preserving joint technologies. For more information, please visit .

Arthrosurface has joined Anika.

For Investor Inquiries:

Anika Therapeutics, Inc.

Mark Namaroff, 781-457-9287

Executive Director, Investor Relations and Corporate Communications

For Media Inquiries:

Greenough

Christine Williamson, 617-922-1289

Senior Vice President



EN
30/09/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Anika Therapeutics Inc.

 PRESS RELEASE

Anika Reports Fourth Quarter and Full Year 2025 Financial Results

Anika Reports Fourth Quarter and Full Year 2025 Financial Results Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target Commercial Channel grew 22% and 15% for Q4 and full year, respectively Generated $11.2 million operating cash flow and $4.4 million in free cash flow for the full year FDA response for Hyalofast® PMA received in January 2026, Anika developing responses for submission BEDFORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain manag...

 PRESS RELEASE

Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Confere...

Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference BEDFORD, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Steve Griffin, President and CEO of Anika, will present at the Canaccord Genuity 2026 Musculoskeletal Conference in New Orleans on Monday, March 2, 2026 at 11:30am CT / 12:30pm ET. Management will also participate in one-on-one investor meetings throughout the event. The presentation will be webcast live on the under the Investors section of Anika Therapeuti...

 PRESS RELEASE

Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on T...

Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026 BEDFORD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and year-end 2025 financial results before the opening of the market on Thursday, February 26, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (internat...

 PRESS RELEASE

Anika Therapeutics Announces Leadership Transition

Anika Therapeutics Announces Leadership Transition Stephen (Steve) Griffin, Current Chief Financial Officer and Chief Operating Officer, Appointed President and Chief Executive OfficerCheryl Blanchard to Become Executive Chair of the Board of Directors BEDFORD, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that Stephen (Steve) Griffin, current Executive Vice President, Chief Financial Officer and Chie...

 PRESS RELEASE

Anika Reports Third Quarter 2025 Financial Results

Anika Reports Third Quarter 2025 Financial Results Commercial Channel revenue up 22% with continued strong Integrity™ Implant System and Hyalofast® growth, and double-digit International OA Pain Management growth Third and final Hyalofast PMA module filed and data released Cingal® achieved commercial milestone of more than one million injections worldwide since 2016 Reaffirming Fiscal 2025 guidance and long-term outlook and commencing a $15 million 10b5-1 share repurchase BEDFORD, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch